Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aerocrine's Niox product has been approved by SFDA, the Chinese registration authority. The company has also entered into a distribution agreement with Bioson that includes sales of both Niox and Niox Mino in China.
Subscribe to our email newsletter
Niox is used for managing airway inflammation by measuring exhaled nitric oxide (NO) levels. Aerocrine and Bioson entered into collaboration in 2004 for distributing Niox in the Chinese market. This agreement has now been expanded to include Niox Mino.
The Chinese market for asthma drugs is estimated to increase from SEK1.2 billion in 2006 to SEK2.3 billion in 2011. Aerocrine said that China represents a significant future prospect for the company.